CN110167938B - 作为Janus激酶抑制剂的新的氨基-咪唑并吡啶衍生物及其医药用途 - Google Patents

作为Janus激酶抑制剂的新的氨基-咪唑并吡啶衍生物及其医药用途 Download PDF

Info

Publication number
CN110167938B
CN110167938B CN201880006261.0A CN201880006261A CN110167938B CN 110167938 B CN110167938 B CN 110167938B CN 201880006261 A CN201880006261 A CN 201880006261A CN 110167938 B CN110167938 B CN 110167938B
Authority
CN
China
Prior art keywords
acetonitrile
cyclohexyl
imidazo
pyridin
trans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880006261.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110167938A (zh
Inventor
J·拉森
M·拉森
L·K·拉斯穆森
A·里岑
T·M·杜斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akileon Ltd
Original Assignee
Leo Pharma AS
Akileon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS, Akileon Ltd filed Critical Leo Pharma AS
Publication of CN110167938A publication Critical patent/CN110167938A/zh
Application granted granted Critical
Publication of CN110167938B publication Critical patent/CN110167938B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201880006261.0A 2017-01-11 2018-01-10 作为Janus激酶抑制剂的新的氨基-咪唑并吡啶衍生物及其医药用途 Active CN110167938B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17151020 2017-01-11
EP17151020.9 2017-01-11
PCT/EP2018/050548 WO2018130563A1 (en) 2017-01-11 2018-01-10 Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof

Publications (2)

Publication Number Publication Date
CN110167938A CN110167938A (zh) 2019-08-23
CN110167938B true CN110167938B (zh) 2024-06-14

Family

ID=57777557

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880006261.0A Active CN110167938B (zh) 2017-01-11 2018-01-10 作为Janus激酶抑制剂的新的氨基-咪唑并吡啶衍生物及其医药用途

Country Status (25)

Country Link
US (1) US10703751B2 (enExample)
EP (1) EP3568396B1 (enExample)
JP (1) JP7009504B2 (enExample)
KR (1) KR102548543B1 (enExample)
CN (1) CN110167938B (enExample)
AU (1) AU2018208516B2 (enExample)
CA (1) CA3045567A1 (enExample)
CY (1) CY1123864T1 (enExample)
DK (1) DK3568396T3 (enExample)
ES (1) ES2846741T3 (enExample)
HR (1) HRP20210095T1 (enExample)
HU (1) HUE052720T2 (enExample)
IL (1) IL267829B (enExample)
LT (1) LT3568396T (enExample)
MX (1) MX389378B (enExample)
MY (1) MY195576A (enExample)
PL (1) PL3568396T3 (enExample)
PT (1) PT3568396T (enExample)
RS (1) RS61317B1 (enExample)
RU (1) RU2019125177A (enExample)
SI (1) SI3568396T1 (enExample)
TW (1) TWI760419B (enExample)
UA (1) UA123972C2 (enExample)
WO (1) WO2018130563A1 (enExample)
ZA (1) ZA201904190B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
MX2022004474A (es) 2016-12-16 2023-08-15 Janssen Pharmaceutica Nv Inhibidores de moléculas pequeñas de la familia de quinasas jak.
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
WO2020007698A1 (en) * 2018-07-06 2020-01-09 Leo Pharma A/S Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof
JP7345220B2 (ja) * 2019-08-30 2023-09-15 ティーエスディー ライフ サイエンス カンパニー リミテッド イミダゾピリジン誘導体及びこれを有効成分として含有する薬学的組成物
US12390451B2 (en) 2021-03-11 2025-08-19 Janssen Pharmaceutica Nv Small molecule inhibitor of the JAK family of kinases
CN119569971B (zh) * 2025-02-07 2025-05-27 吉林大学 一种用于蛋白质磷酸化和棕榈酰化修饰同时筛选的Janus材料的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104955824A (zh) * 2012-11-20 2015-09-30 基因泰克公司 作为含t790m的egfr突变体的抑制剂的氨基嘧啶化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100375A1 (en) * 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
CN102712640A (zh) 2010-01-12 2012-10-03 弗·哈夫曼-拉罗切有限公司 三环杂环化合物、其组合物和应用方法
SG10201505997TA (en) * 2010-08-05 2015-09-29 Amgen Inc Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
UY34616A (es) 2012-02-10 2013-09-30 Galapagos Nv Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
CN104098563A (zh) 2013-04-02 2014-10-15 山东亨利医药科技有限责任公司 Jnk抑制剂化合物
SG11201609016VA (en) 2014-04-30 2016-11-29 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
EA201990523A1 (ru) 2016-10-03 2019-10-31 НОВЫЕ СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Jak1 И ИХ ПРИМЕНЕНИЕ
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104955824A (zh) * 2012-11-20 2015-09-30 基因泰克公司 作为含t790m的egfr突变体的抑制剂的氨基嘧啶化合物

Also Published As

Publication number Publication date
NZ754922A (en) 2025-11-28
CA3045567A1 (en) 2018-07-19
JP2020504186A (ja) 2020-02-06
TWI760419B (zh) 2022-04-11
CN110167938A (zh) 2019-08-23
BR112019014191A2 (pt) 2020-02-11
IL267829A (en) 2019-09-26
HRP20210095T1 (hr) 2021-03-05
MX389378B (es) 2025-03-20
RU2019125177A (ru) 2021-02-15
ES2846741T3 (es) 2021-07-29
MY195576A (en) 2023-02-02
PL3568396T3 (pl) 2021-05-31
US20190367512A1 (en) 2019-12-05
DK3568396T3 (da) 2021-01-18
WO2018130563A1 (en) 2018-07-19
EP3568396A1 (en) 2019-11-20
KR102548543B1 (ko) 2023-06-29
PT3568396T (pt) 2021-02-09
AU2018208516B2 (en) 2021-07-08
LT3568396T (lt) 2021-02-10
CY1123864T1 (el) 2022-05-27
TW201829407A (zh) 2018-08-16
IL267829B (en) 2022-02-01
US10703751B2 (en) 2020-07-07
EP3568396B1 (en) 2020-11-11
ZA201904190B (en) 2020-10-28
RU2019125177A3 (enExample) 2021-05-11
KR20190103231A (ko) 2019-09-04
SI3568396T1 (sl) 2021-04-30
RS61317B1 (sr) 2021-02-26
HUE052720T2 (hu) 2021-05-28
JP7009504B2 (ja) 2022-01-25
AU2018208516A1 (en) 2019-07-11
MX2019008331A (es) 2020-01-14
UA123972C2 (uk) 2021-06-30

Similar Documents

Publication Publication Date Title
EP3190889B1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP2964223B1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
TWI760419B (zh) 作為酪胺酸蛋白激酶抑制劑之新穎的胺基-咪唑并吡啶衍生物及其醫藥用途
CA2790070C (en) Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
KR20240055788A (ko) 신규한 ras 억제제
CN105263934B (zh) 作为bet抑制剂的吡唑并‑吡咯烷‑4‑酮衍生物及其在治疗疾病中的用途
CN115590854A (zh) 哒嗪基噻唑甲酰胺类化合物
CA2818545A1 (en) Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CN105452239A (zh) 作为jak抑制剂的联吡唑衍生物
RU2764980C2 (ru) Бициклические амины в качестве новых ингибиторов jak-киназы
CN112898269A (zh) 化合物的结晶形式
WO2019011228A1 (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
WO2025087267A1 (zh) 一种含有噻唑基的哌啶并嘧啶类衍生物、其制备方法及其医药上的应用
CN110248663A (zh) 作为新型JAK激酶抑制剂的5-(7H-吡咯并[2,3-d]嘧啶-4-基)-5-氮杂螺[2.5]辛烷-8-甲酸衍生物
TWI924689B (zh) 嘧啶酮類化合物及其用途
CN105102435A (zh) 用作激酶活性调节剂的新颖的咪唑-哌啶基衍生物
HK40013317B (en) Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
CA3222404A1 (en) Heterocyclic jak inhibitor
HK40013317A (en) Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
BR112019014191B1 (pt) Composto e composição farmacêutica
WO2025151602A1 (en) Heteroaryl compounds as ligand directed degraders of irak4
KR20260010408A (ko) Irak4의 리간드 지정 분해제로서의 헤테로아릴 화합물
HK40053244A (en) Pyridazinone derivative

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013317

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20221109

Address after: Helsingborg

Applicant after: Akileon Ltd.

Address before: Rupp, Denmark

Applicant before: LEO PHARMA A/S

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant